← Search & browse all drugs
CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › Renin-inhibitors
aliskiren, amlodipine and hydrochlorothiazide
C09XA54
Forms & Strengths
- Tablets: aliskiren 150-300 mg / amlodipine 5-10 mg / hydrochlorothiazide 12.5-25 mg
- Fixed-dose combination
Adult Dosing
- Recommended starting dose: aliskiren 150 mg / amlodipine 5 mg / hydrochlorothiazide 12.5 mg orally once daily
- Titrate to maximum dose: aliskiren 300 mg / amlodipine 10 mg / hydrochlorothiazide 25 mg orally once daily
- Adjust doses based on blood pressure response
Pediatric Dosing
- Not recommended for pediatric patients under 18 years
- Safety and efficacy not established in pediatric population
Indications
- Hypertension
- Treatment of patients not adequately controlled with any two of the following: aliskiren, amlodipine, or hydrochlorothiazide
Mechanism of Action
- Aliskiren: direct renin inhibitor, reducing plasma renin activity
- Amlodipine: calcium channel blocker, inhibiting L-type calcium channels
- Hydrochlorothiazide: thiazide diuretic, inhibiting sodium reabsorption in the kidneys
Contraindications
- Anuria
- Hypersensitivity to any component of the product
- Severe renal impairment (GFR <30 mL/min)
- Severe hepatic impairment
Adverse Reactions
- Edema
- Dizziness
- Headache
- Fatigue
- Gastrointestinal disorders
- Electrolyte imbalances
- Renal impairment
Drug Interactions
- NSAIDs: increased risk of renal impairment and hyperkalemia
- Potassium supplements: increased risk of hyperkalemia
- Lithium: increased risk of lithium toxicity
- ACE inhibitors and ARBs: increased risk of hyperkalemia and renal impairment
- Cyclosporine: increased risk of hyperkalemia
Curated Content: Needs Vetting Before Put to Clinical Use